10月29日，民生健康（301507）药业股份有限公司(301507.SZ)披露的2025年第三季度报告显示，公司 前三季度实现营业总收入6.23亿元，同比增长19.78%；归母净利润1.14亿元，同比增长32.77%。在"十 五五"规划建议明确提出实施健康优先发展战略的宏观背景下，民生健康作为集非处方药、保健食品、 功能性食品研发、生产、销售于一体的高新技术企业，正迎来新的发展机遇。 民生健康长期以来以"21金维他"为核心产品，在维生素与矿物质补充剂领域占据重要地位。其主营业务 收入中，维生素与矿物质补充剂系列占比高达99.69%，这使得公司一直在积极寻求产品多元化，以构 建更加均衡的业务结构。2025年9月，在公司上市两周年庆之际，民生健康重磅推出了专业医美赛道新 品"肌素然"与戒烟控烟产品"乐速克"，进一步拓展了大健康产品矩阵。"肌素然"品牌聚焦修复与抗衰领 域，凭借医药级研发背书和扎实功效验证，打造安全高效的产品体系。 该系列产品目前包含多款二类医疗器械护肤品，结合科学配方和多项专利技术，帮助消费者实现肌肤健 康管理。而"乐速克"作为专业戒烟控烟产品，提供科学戒控烟全周期解决方案，构建了从评估、规划到 ...

Summary of Stock Buyback Activities on October 30 Core Insights - On October 30, a total of 26 companies announced 27 stock buyback-related updates, indicating a significant activity in the market [1] Group 1: New Buyback Proposals - 16 companies disclosed stock buyback proposals for the first time, with 6 companies proposing buyback amounts exceeding 10 million [1] - The highest proposed buyback amounts were from HeMai Co., Ltd. (up to 200 million), Sanli Shi (60 million), and Minsheng Health (50.544 million) [1] Group 2: Approved Buyback Plans - 2 companies had their buyback plans approved by shareholders, with the highest proposed amounts from Dayu Biological (up to 5.596 million) and New Weiling (20,200) [1] Group 3: Buyback Implementation Progress - 2 companies reported on the implementation of their buyback plans, with the highest amounts from Guyue Longshan (186 million) and Jiayi Co. (99.0246 million) [1] Group 4: Completed Buybacks - 5 companies completed buybacks exceeding 10 million, with the highest completed amounts from Huafa Co. (310 million), Shenzhou Digital (203 million), and Ruoyu Chen (200 million) [1] - As of October 30, a total of 1711 buyback plans have been completed this year, involving 1281 companies, with 330 companies completing buybacks exceeding 100 million [1] - The leading companies in completed buyback amounts include Kweichow Moutai (6 billion), Muyuan Foods (3 billion), and COSCO Shipping Holdings (2.146 billion) [1]

证券代码：301507 证券简称：民生健康 公告编号：2025-048 杭州民生健康药业股份有限公司（以下简称"公司"）于2025年10月24日收到 公司实际控制人、董事长竺福江先生出具的《关于提议杭州民生健康药业股份有 限公司实施第二期公司股份回购的函》。竺福江先生提议公司以自有资金通过集 中竞价交易方式实施第二期公司股份回购，用于股权激励。提议函具体内容如下： 一、提议人的基本情况及提议时间 1、提议人：公司实际控制人、董事长竺福江先生 2、是否享有提案权：是 3、提议时间：2025年10月24日 二、提议回购股份的原因和目的 公司自成立以来，专注于大健康领域，是集非处方药、保健食品、功能性食 品研发、生产、销售于一体的高新技术企业。公司以维生素与矿物质补充剂系列 产品为业务发展核心，一方面持续深耕研发创新，通过产品迭代升级筑牢专业壁 垒，构建起多维度、阶梯式的产品矩阵；另一方面稳步推进治疗型 OTC 用药、 益生菌等业务板块，进一步夯实并拓宽产品护城河。 杭州民生健康药业股份有限公司 关于公司实际控制人、董事长提议实施第二期 公司股份回购的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不 ...

证券代码：301507 证券简称：民生健康 公告编号：2025-051 关于第二期以集中竞价交易方式回购公司股份 方案的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 重要内容提示： （一）回购方案的主要内容 1.回购股份的种类：杭州民生健康药业股份有限公司（以下简称"公司"） 已发行的无限售条件的人民币普通股（A股）股票。 2.回购股份的用途：拟用于股权激励。若公司未能在股份回购实施结果暨股 份变动公告日后3年内使用完毕已回购股份，尚未使用的已回购股份将予以注销。 如国家对相关政策作调整，则本回购方案按调整后的政策实行。 3.回购方式：集中竞价交易方式。 杭州民生健康药业股份有限公司 2.本次回购事项存在因发生对本公司股票交易价格产生重大影响的重大事 项，或生产经营、财务状况、外部客观情况发生重大变化，或其他导致公司董事 会决定终止本次回购方案、公司不符合法律法规规定的回购股份条件等，而导致 回购方案无法顺利实施或根据相关规定变更/终止的风险。 4.回购股份的价格区间：不超过人民币21.06元/股，不超过董事会通过回购 股份决议前30个交易日公司 ...

Financial Performance - The company's revenue for the third quarter reached ¥160,167,138.81, representing a year-on-year increase of 30.84%[5] - Net profit attributable to shareholders was ¥32,011,393.42, a significant increase of 259.31% compared to the same period last year[5] - The basic earnings per share rose to ¥0.09, reflecting a 350.00% increase year-on-year[5] - The total operating revenue for the current period reached ¥622,651,417.80, an increase of approximately 19.7% compared to ¥519,847,972.13 in the previous period[30] - The company's net profit from investment was ¥9,582,086.08, compared to ¥4,239,651.46 in the previous period, indicating a significant increase[30] - The net profit for the current period is CNY 115,084,802.95, an increase from CNY 86,178,415.70 in the previous period, representing a growth of approximately 33.5%[31] - The operating profit for the current period is CNY 132,723,253.46, compared to CNY 100,821,117.14 in the previous period, indicating a growth of about 31.6%[31] - The total comprehensive income for the current period is CNY 115,084,802.95, compared to CNY 86,178,415.70 in the previous period, indicating an increase of approximately 33.5%[31] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,027,807,601.04, marking a 16.23% increase from the end of the previous year[5] - The total assets of the company as of September 30, 2025, were ¥2,027,807,601.04, up from ¥1,744,608,477.33, representing an increase of about 16.3%[29] - The total liabilities increased to ¥302,613,127.28 from ¥213,762,236.27, reflecting a rise of approximately 41.5%[29] - The company's total equity rose to ¥1,725,194,473.76 from ¥1,530,846,241.06, marking an increase of about 12.7%[29] Cash Flow - The company reported a net cash flow from operating activities of ¥158,147,262.90, up 56.52% year-on-year[5] - Cash flow from operating activities for the current period is CNY 158,147,262.90, up from CNY 101,039,367.62 in the previous period, reflecting a growth of approximately 56.5%[33] - The company reported a total operating cash inflow of CNY 730,445,100.58, compared to CNY 603,654,399.05 in the previous period, reflecting an increase of about 21%[33] - The cash and cash equivalents decreased to ¥253,346,395.38 from ¥338,733,013.65, a decline of approximately 25.2%[27] - The cash and cash equivalents at the end of the period are CNY 202,526,467.85, down from CNY 389,824,520.26 in the previous period[34] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,684[17] - The largest shareholder, Hangzhou Minsheng Pharmaceutical Co., Ltd., holds 66.75% of shares, totaling 238,000,000 shares[17] - The top ten shareholders include various entities, with the second-largest shareholder holding 0.90% of shares, totaling 3,208,989 shares[17] - The company has not disclosed any changes in the top ten shareholders due to margin trading activities[18] - The total number of preferred shareholders at the end of the reporting period is not applicable[19] - The company has not identified any other significant matters related to shareholder relationships or actions[18] Share Repurchase and Incentives - The company plans to repurchase between 1.3 million to 1.45 million shares at a maximum price of RMB 19.80 per share, with a total expected expenditure of up to RMB 28.71 million[21] - As of September 25, 2025, the company has repurchased a total of 1,344,900 shares, representing 0.38% of the total share capital, with a total payment of RMB 17,497,776[22] - The highest transaction price during the repurchase was RMB 14.03 per share, and the lowest was RMB 11.83 per share[22] - The company has a total of 900,000 restricted shares scheduled for release on December 26, 2025, as part of an equity incentive plan[20] - The company completed the first vesting period of the 2024 restricted stock incentive plan, with 1,328,000 shares vesting, accounting for 0.37% of the total share capital[23] Future Plans and Strategies - The company plans to continue optimizing inventory management and enhancing cash flow management strategies in the future[15] - The company plans to apply for the lifting of restrictions on the vested shares after a 3-month lock-up period[24] Other Financial Metrics - Total operating costs amounted to ¥527,856,658.74, up from ¥429,009,479.08, reflecting a growth of about 23%[30] - Research and development expenses for the current period were ¥22,269,360.70, slightly higher than ¥21,522,017.88 in the previous period[30] - The cash flow from financing activities resulted in a net outflow of CNY 93,832,141.12, compared to a net outflow of CNY 36,679,880.14 in the previous period[34] - Investment income increased by 126.0% to ¥9,582,086.08 due to adjustments in financial management strategies[13] - The fair value change income surged by 698.6% to ¥26,960,798.37, attributed to the appreciation of shares in a related company[13] Audit Status - The company has not undergone an audit for the third quarter financial report[35]

杭州民生健康药业股份有限公司 第二届董事会第十一次会议决议公告 证券代码：301507 证券简称：民生健康 公告编号：2025-049 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 杭州民生健康药业股份有限公司（以下简称"公司"）第二届董事会第十一次 会议于2025年10月28日以现场及通讯方式召开，本次会议通知于2025年10月24 日以书面、通讯等方式发出。会议由竺福江先生召集并主持，应到董事9人，实 到董事9人，其中董事丁建萍、刘玉龙、朱狄敏以通讯方式出席会议，全体高级 管理人员列席会议。本次会议的召集、召开符合《中华人民共和国公司法》（以 下简称"《公司法》"）、《杭州民生健康药业股份有限公司章程》（以下简称"《公 司章程》"）以及有关法律、法规的有关规定，所作决议合法有效。 二、董事会会议审议情况 经全体董事审议，作出如下决议： （一）审议通过了《关于公司<2025 年第三季度报告>的议案》 经审议，董事会认为：公司《2025 年第三季度报告》的编制及审核程序符 合法律、行政法规和中国证监会及深圳证券交易所的规定，报告内容真 ...

Core Viewpoint - The article highlights the proactive measures taken by the Jiangkou Hui Autonomous Town People's Congress in Ning'an County to ensure the safety of drugs and medical devices through a collaborative supervision model involving local authorities and market regulation departments [2] Group 1: Supervision and Inspection - The local People's Congress emphasizes the importance of drug and medical device safety as a public concern, organizing representatives to participate in comprehensive inspections covering all key stages from procurement to usage [2] - The inspections revealed issues such as incomplete temperature and humidity records in health center pharmacies, unclear storage area labeling, and non-compliance with pricing regulations in some retail pharmacies [2] Group 2: Problem Rectification - Following the inspections, the local People's Congress provided on-site supervisory recommendations to the market regulation department to address the identified issues [2] - The focus is on ensuring that corrective actions are implemented effectively to enhance compliance and safety standards in the healthcare sector [2] Group 3: Long-term Mechanism - A long-term mechanism is being established that combines "People's Congress supervision + departmental regulation + public participation" to maintain ongoing oversight of drug and medical device safety [2] - Regular inspections and checks will be organized to integrate special supervision with daily regulatory practices, ensuring a consistent focus on public health and safety [2]

Core Viewpoint - Minsheng Health's stock experienced a slight decline of 0.58% on October 17, with a trading volume of 39.39 million yuan, indicating a stable market presence despite minor fluctuations [1]. Financing Summary - On October 17, Minsheng Health had a financing buy-in amount of 4.92 million yuan, with a net financing buy of 1.80 million yuan after repayments [1]. - The total financing and securities balance reached 99.86 million yuan, accounting for 6.62% of the circulating market value, which is above the 70th percentile of the past year, indicating a high level of financing activity [1]. - There were no securities sold or repaid on the same day, with a total securities balance of 0.00 yuan, also reflecting a high percentile position [1]. Company Performance - As of June 30, the number of shareholders for Minsheng Health was 21,500, a decrease of 0.41%, while the average circulating shares per person increased by 0.41% to 5,137 shares [2]. - For the first half of 2025, Minsheng Health reported a revenue of 462 million yuan, representing a year-on-year growth of 16.37%, and a net profit attributable to shareholders of 82.41 million yuan, up 6.65% year-on-year [2]. Dividend and Shareholding - Since its A-share listing, Minsheng Health has distributed a total of 71.20 million yuan in dividends [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 1.71 million shares, an increase of 714,100 shares compared to the previous period [3].

Core Insights - The article discusses the recent financial performance of a specific company, highlighting significant revenue growth and strategic initiatives taken to enhance market position [1] Financial Performance - The company reported a revenue increase of 25% year-over-year, reaching $2.5 billion in the last quarter [1] - Net income rose to $300 million, reflecting a 15% increase compared to the previous year [1] Strategic Initiatives - The company has launched a new product line aimed at expanding its market share in the technology sector [1] - Investments in research and development have increased by 20%, indicating a commitment to innovation and long-term growth [1] Market Position - The company has gained a competitive edge, now holding a 30% market share in its primary industry [1] - Partnerships with key industry players have been established to enhance distribution channels and customer reach [1]

Core Viewpoint - The company is advancing its strategic upgrade through a dual approach of "century-old pharmaceutical enterprise + innovation engine" in line with the "Healthy China 2030" initiative [1] Group 1: Development Strategy - The company has introduced a "Four New" strategy focusing on new products, new models, new businesses, and new projects to adapt to a rapidly changing market environment [2][3] - The company emphasizes that innovation is the core driving force for its development, with a focus on product innovation and user experience [2][3] - The company is expanding its product matrix, exemplified by the evolution of its classic product, 21 Jin Weita, from a single product to over fifty SKUs targeting specific demographics [2] Group 2: Business Expansion - The company is enhancing its industry chain layout through mergers and acquisitions, with a planned acquisition of a strain raw material company in 2024 to strengthen its probiotics business [2][4] - The company has adopted a flexible organizational structure to quickly respond to market changes, balancing traditional and emerging sales channels [3][6] - The company is committed to exploring related fields for new projects, ensuring that all new initiatives revolve around product innovation [3] Group 3: Probiotics Market Focus - The company views the probiotics sector as a key growth engine, with the market size in China exceeding 100 billion yuan [4] - The company's core competitiveness in probiotics stems from its "Yanhuang Strain Resource Library" and advanced encapsulation technology, which are based on regional differences in gut microbiota [4][5] - The company has established a precise and efficient efficacy expression technology system to ensure the survival and colonization rates of probiotics [4] Group 4: Business Model and Channel Strategy - The company employs a multi-faceted business model combining strain raw materials, OEM/ODM, and proprietary brands, facilitated by a cross-functional "Product Innovation Center" [5] - The company is actively integrating online and offline sales strategies, utilizing pharmacies and social media platforms to enhance brand influence [6] - The company aims to provide targeted health solutions rather than generic gut health products, focusing on areas like weight management and cognitive regulation [6] Group 5: Capital Market and Governance - The company successfully went public in 2023, which has led to a fundamental change in its operations, emphasizing compliance and governance [6][7] - The public listing has diversified employee incentive methods, allowing for stock options and employee shareholding plans [7] - The company sees the public platform as an opportunity for business expansion and potential acquisitions, while maintaining a cautious approach to ensure quality partnerships [7] Group 6: Future Outlook - The company plans to continue focusing on product innovation and the "Four New" strategy, viewing the public listing as a new starting point for higher quality development [7] - The company emphasizes the importance of innovation, culture, and teamwork in the successful succession of private enterprises [7]